Basics Zymeworks Inc. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. IPO Date: April 28, 2017 Sector: Healthcare Industry: Biotech Market Cap: $811.12M Activated in VL: True Average Daily Range Avg Daily Range: $0.46 | 2.64% Avg Daily Range (30 D): $0.25 | 2.08% Avg Daily Range (90 D): $0.32 | 2.56% Institutional Daily Volume Avg Daily Volume: .43M Avg Daily Volume (30 D): .33M Avg Daily Volume (90 D): .46M Trade Size Avg Trade Size (Sh.): 106 Avg Trade Size (Sh.) (30 D): 52 Avg Trade Size (Sh.) (90 D): 65 Institutional Trades Total Inst.Trades: 1,428 Avg Inst. Trade: $1.74M Avg Inst. Trade (30 D): $.91M Avg Inst. Trade (90 D): $1.08M Avg Inst. Trade Volume: .12M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.33M Avg Closing Trade (30 D): $.91M Avg Closing Trade (90 D): $1.1M Avg Closing Volume: 105.49K     News May 30, 2025 @ 10:00 AM Zymeworks Announces NMPA Approval of Zanidatamab i... Source: N/A May 22, 2025 @ 9:00 PM Zymeworks Announces Presentations Highlighting Bre... Source: Zymeworks Inc. May 21, 2025 @ 10:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: N/A Apr 17, 2025 @ 10:00 AM Zymeworks to Report First Quarter 2025 Financial R... Source: N/A Feb 26, 2025 @ 11:00 AM Zymeworks Announces Achievement of $14 Million Mil... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.5 $-.3 $-.32 Diluted EPS $-1.5 $-.3 $-.32 Revenue $ 93.38M $ 27.11M $ 31.03M Gross Profit $ $ $ Net Income / Loss $ -113.68M $ -22.64M $ -23.51M Operating Income / Loss $ -124.92M $ -25.61M $ -22.22M Cost of Revenue $ $ $ Net Cash Flow $ -38.61M $ 10.1M $ -56.25M PE Ratio